Aurinia Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 1/4
Aurinia Pharmaceuticals CEO'su Peter Greenleaf, Apr2019 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 10.57M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler $ 2.25M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 1.3 yıldır.
Anahtar bilgiler
Peter Greenleaf
İcra Kurulu Başkanı
US$10.6m
Toplam tazminat
| CEO maaş yüzdesi | 7.8% |
| CEO görev süresi | 5.6yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 4.4yrs |
| Yönetim Kurulu ortalama görev süresi | 1.3yrs |
Son yönetim güncellemeleri
Recent updates
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06
Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$11m | US$823k | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Tazminat ve Piyasa: Peter 'nin toplam tazminatı ($USD 10.57M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).
Tazminat ve Kazançlar: Peter şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Peter Greenleaf (54 yo)
5.6yrs
Görev süresi
US$10,573,359
Tazminat
Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% $ 2.2m | |
| Chief Financial Officer | 4.6yrs | US$3.98m | 0.078% $ 808.5k | |
| Chief Operations Officer | no data | US$4.56m | 0.11% $ 1.1m | |
| Executive Vice President of General Counsel | 4yrs | US$3.60m | 0.055% $ 565.0k | |
| Head of the Corporate Communications & Investor Relations | no data | Veri yok | Veri yok | |
| Chief Business Officer | 4.4yrs | US$702.00k | Veri yok | |
| Senior Vice President of Global Regulatory Affairs | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 2.3yrs | Veri yok | 0.071% $ 732.0k | |
| Chief Medical Officer | no data | Veri yok | Veri yok | |
| Senior Vice President of Quality | no data | Veri yok | Veri yok | |
| Senior Vice President of Manufacturing & Supply Chain | no data | Veri yok | Veri yok | |
| Vice President of Investor Relation | no data | Veri yok | Veri yok |
4.4yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: AUPH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% $ 2.2m | |
| Chairman | less than a year | Veri yok | Veri yok | |
| Director | 1.2yrs | US$474.21k | 0% $ 0 | |
| Independent Director | 5yrs | US$267.28k | 0.010% $ 106.1k | |
| Independent Director | 1.3yrs | US$361.51k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$359.41k | 0% $ 0 | |
| Independent Non-Executive Director | 9.5yrs | US$249.92k | 0.031% $ 319.9k |
1.3yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AUPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.